Calidi Biotherapeutics stock was up 171.84% in pre-market trading on Wednesday, following a 39.47% rally yesterday. However, ...

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Calidi Biotherapeutics announced a public offering of 5 million shares at $0.85 each, aiming for $4.25 million in proceeds. Quiver AI Summary Calidi Biotherapeutics, Inc. announced the pricing of ...

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.

Calidi Biotherapeutics announces recruitment for CLD-101 clinical trial targeting high-grade glioma with allogeneic neural stem cells.

About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer.

About Calidi Biotherapeutics: Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer.

About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer.

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results Nov. 12, 2024 5:29 PM ET Calidi Biotherapeutics, Inc. (CLDI) ...